Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Revenue projections:

Revenue projections for CIPLA
Revenue projections for CIPLA

Cipla Limited's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 3.443000
forwardPE 22.687496
debtToEquity 1.778000
earningsGrowth -0.546000
revenueGrowth -0.021000
grossMargins 0.647470
operatingMargins 0.112620
trailingEps 47.960000
forwardEps 63.435820

CIPLA's current ratio, being 3.443, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, CIPLA is well-equipped to meet its immediate financial obligations without any difficulties.
CIPLA's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
CIPLA's low earnings and revenue growth point to a possible reduction in profits. This trend suggests that the company may face difficulties in maintaining its profitability and could be a cause for concern among investors.
CIPLA's negative gross and operating margins point to losses in both production and operations. This suggests the company is facing financial challenges and may need to address cost management or improve revenue generation.
CIPLA's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that CIPLA is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.

Price projections:

Price projections for CIPLA
Price projections for CIPLA

CIPLA's price has consistently hovered near the lower end of price projections. This trend suggests that the stock is underperforming relative to analyst expectations, indicating a potential lack of momentum for upward movement in the near future.

Recommendation changes over time:

Recommendations trend for CIPLA
Recommendations trend for CIPLA


Recent analysis shows a strong buy bias for CIPLA, encouraging investors to view it as a solid investment option. The positive sentiment surrounding CIPLA suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.